Antony Odell, chief executive of Tissue Regenix PLC (LON:TRX) tells Proactive they're spending US$30mln on Texas-based rival, Cellright Technologies, which will catapult them to the front of the growing US market for regenerative medicine and bone grafts.
Tissue Regenix chief Antony Odell on their 'transformational' Cellright acquisition
Quick facts: Tissue Regenix Group PLC
Price: 1.55 GBX
Market Cap: £18.17 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE